Mayer-Hamblett, N., & VanDevanter, D. (2020). Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis. Trends Mol Med.
シカゴスタイル引用形Mayer-Hamblett, N., , DR VanDevanter. "Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics Through Clinical Trials in Cystic Fibrosis." Trends Mol Med 2020.
MLA引用形式Mayer-Hamblett, N., , DR VanDevanter. "Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics Through Clinical Trials in Cystic Fibrosis." Trends Mol Med 2020.
警告: この引用は必ずしも正確ではありません.